BAAM
ALXN

Baker Avenue Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Baker Avenue Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,750
Closed -$429K – 248
2020
Q3 		$429K Buy
+3,750
New +$405K 0.03% 173

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Baker Avenue Asset Management's ALXN Position: Q4 2020 in Review

Baker Avenue Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 3,750 shares — an estimated $429K sold.

Baker Avenue Asset Management first reported a position in ALXN in Q3 2020 and held it in 1 quarter. The position peaked at $429K in Q3 2020. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Baker Avenue Asset Management reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Baker Avenue Asset Management sold 3,750 Alexion Pharmaceuticals shares in Q4 2020, an estimated $429K.
  • Baker Avenue Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Baker Avenue Asset Management's Alexion Pharmaceuticals position peaked at $429K in Q3 2020.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Baker Avenue Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.